再鼎医药：上半年产品收入净额同比增加15%

Core Viewpoint - Zai Ding Pharmaceutical reported a 15% year-on-year increase in product revenue net to $215 million for the first half of the year, indicating strong growth in its operations [1] Financial Performance - Product revenue net increased by 15% to $215 million [1] - Research and development expenses decreased by 4% to $111 million [1] - Net loss reduced by $44.6 million year-on-year to $89.2 million, primarily due to revenue growth outpacing net operating expenses [1] - Basic and diluted loss per share was $0.08 [1]